P. Rassek

Safety and Survival Outcomes of 177Lu-Prostate-Specific Membrane Antigen Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer with Prior 223Ra treatment: The RALU Study

K. Rahbar, H. Dittmann, R. Bundschuh, 2022, The Journal of Nuclear Medicine.

Safety and survival outcomes in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) treated with lutetium-177–prostate-specific membrane antigen (177Lu-PSMA) after radium-223 (223Ra): Interim analysis of the RALU study.

K. Rahbar, H. Dittmann, R. Bundschuh, 2022, Journal of Clinical Oncology.

Diffusion-Weighted MRI for Treatment Response Assessment in Osteoblastic Metastases—A Repeatability Study

M. Eveslage, B. Noto, A. Riegel, 2023, Cancers.

[ 18 F]-PSMA-1007-PET for evaluation of kidney function

K. Rahbar, M. Schäfers, P. Backhaus, 2023, NuclearMedicine.

177Lu-Prostate-Specific Membrane Antigen Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer and Prior 223Ra (RALU Study)

R. Bundschuh, F. Verholen, Markus Essler, 2023, The Journal of Nuclear Medicine.

Safety and Survival Outcomes of 177 Lu-Prostate-Specific Membrane Antigen Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer with Prior 223 Ra treatment: The RALU Study

K. Rahbar, R. Bundschuh, O. Sartor, 2023 .

Safety and Survival Outcomes of Lutetium-177–Prostate-Specific Membrane Antigen Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer with prior Radium-223 treatment: The RALU Study

K. Rahbar, R. Bundschuh, M. Kurtinecz, 2022 .

Determination of the optimal imaging protocol for [18F]PSMA-PET-CT for the detection of bone metastases in prostate cancer patients.

P. Rassek, Kambiz Rahbar, Michael Schäfers, 2024, Nuklearmedizin. Nuclear medicine.